OncoMed Pharmaceuticals - Top 20 VC deals of 2008

Oncomed Pharmaceuticals, Fiercebiotech's top venture capital deals of 2008Company: OncoMed Pharmaceuticals
Based: Redwood City, CA
Amount: $106.96

Investors: Morgenthaler Ventures, Undisclosed Venture Firm, Bay Partners, Latterell Venture Partners, Vertical Group, The Nomura International, GSK Ventures, Adams Street Partners, De Novo Ventures, U.S. Venture Partners, Undisclosed Firm.

Scoop: OncoMed Pharmaceuticals is targeting cancer by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells. The bulk of OncoMed's 2008 haul came from a massive $93.3 million round in November. It will be used to advance the company's cancer stem cell antibody programs--including lead compound OMP-21M18 and a second antibody--through Phase II clinical trials. OncoMed was a 2008 Fierce 15 company.

OncoMed Pharmaceuticals - Top 20 VC deals of 2008

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.